Caveolin-1 regulates glioblastoma aggressiveness through the control of α5β1 integrin expression and modulates glioblastoma responsiveness to SJ749, an α5β1 integrin antagonist

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1793, Issue 2, 2009, Pages 354-367

  Martin, Sophie ^a   Cosset, Erika C ^a   Terrand, Jérôme ^a   Maglott, Anne ^a   Takeda, Ken ^a   Dontenwill, Monique ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

5 1 integrin; 5 1 integrin antagonist; Caveolin 1; Human glioma; SJ749

Indexed keywords

2 [(2,4,6 TRIMETHYLPHENYL) SULFONYL] AMINO 3 [7 BENZYLOXYCARBONYL 8 (2 PYRIDINYLAMINOMETHYL) 1 OXA 2,7 DIAZASPIRO (4,4) NON 2 EN 3 YL) CARBONYLAMINO) PROPIONIC ACID]; CAVEOLIN 1; PROPIONIC ACID DERIVATIVE; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 5;

ARTICLE; CELL LINE; CLONOGENESIS; GENE IDENTIFICATION; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL;

CAVEOLIN 1; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; INTEGRIN ALPHA5BETA1; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PHENOTYPE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROPIONIC ACIDS; PYRIDINES; SPIRO COMPOUNDS; TUMOR STEM CELL ASSAY;

EID: 58549106104     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2008.09.019     Document Type: Article

References (45)

1. Liscovitch M., Burgermeister E., Jain N., Ravid D., Shatz M., and Tencer L. Caveolin and Cancer (2005), Humana Press
2. Carver L.A., and Schnitzer J.E. Caveolae: mining little caves for new cancer targets. Nat. Rev. Cancer 3 (2003) 571-581
3. van Deurs B., Roepstorff K., Hommelgaard A.M., and Sandvig. Caveolae: anchored, multifunctional platforms in the lipid ocean. Trends Cell Biol. 13 (2003) 92-100
4. Glait C., Tencer L., Ravid D., Sarfstein R., Liscovitch M., and Werner H. Caveolin-1 up-regulates IGF-I receptor gene transcription in breast cancer cells via Sp1- and p53-dependent pathways. Exp. Cell Res. 312 (2006) 3899-3908
5. Glait C., Ravid D., Lee S.W., Liscovitch M., and Werner H. Caveolin-1 controls BRCA1 gene expression and cellular localization in human breast cancer cells. FEBS Lett. 580 (2006) 5268-5274
6. Li T., Sotgia F., Vuolo M.A., Li M., Yang W.C., Pestell R.G., Sparano J.A., and Lisanti M.P. Caveolin-1 mutations in human breast cancer: functional association with estrogen receptor alpha-positive status. Am. J. Pathol. 168 (2006) 1998-2013
7. Hulit J., Bash T., Fu M., Galbiati F., Albanese C., Sage D.R., Schlegel A., Zhurinsky J., Shtutman M., Ben-Ze'ev A., Lisanti M.P., and Pestell R.G. The cyclin D1 gene is transcriptionally repressed by caveolin-1. J. Biol. Chem. 275 (2000) 21203-21209
8. Torres V.A., Tapia J.C., Rodriguez D.A., Parraga M., Lisboa P., Montoya M., Leyton L., and Quest A.F. Caveolin-1 controls cell proliferation and cell death by suppressing expression of the inhibitor of apoptosis protein survivin. J. Cell Sci. 119 (2006) 1812-1823
9. Ravid D., Maor S., Werner H., and Liscovitch M. Caveolin-1 inhibits anoikis and promotes survival signaling in cancer cells. Adv. Enzyme Regul. 46 (2006) 163-175
10. Quest A.F., Leyton L., and Parraga M. Caveolins, caveolae, and lipid rafts in cellular transport, signaling, and disease. Biochem. Cell Biol. 82 (2004) 129-144
11. Grossman S.A., and Batara J.F. Current management of glioblastoma multiforme. Semin. Oncol. 31 (2004) 635-644
12. Boon K., Edwards J.B., Eberhart C.G., and Riggins G.J. Identification of astrocytoma associated genes including cell surface markers. BMC Cancer 4 (2004) 39
13. Sallinen S.L., Sallinen P.K., Haapasalo H.K., Helin H.J., Helen P.T., Schraml P., Kallioniemi O.P., and Kononen J. Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res. 60 (2000) 6617-6622
14. Van Meter T., Dumur C., Hafez N., Garrett C., Fillmore H., and Broaddus W.C. Microarray analysis of MRI-defined tissue samples in glioblastoma reveals differences in regional expression of therapeutic targets. Diagn. Mol. Pathol. 15 (2006) 195-205
15. Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P., Iyer V., Jeffrey S.S., Van de Rijn M., Waltham M., Pergamenschikov A., Lee J.C., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., and Brown P.O. Systematic variation in gene expression patterns in human cancer cell lines. Nat. Genet. 24 (2000) 227-235
16. Nigro J.M., Misra A., Zhang L., Smirnov I., Colman H., Griffin C., Ozburn N., Chen M., Pan E., Koul D., Yung W.K., Feuerstein B.G., and Aldape K.D. Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res. 65 (2005) 1678-1686
17. Cassoni P., Senetta R., Castellano I., Ortolan E., Bosco M., Magnani I., and Ducati A. Caveolin-1 expression is variably displayed in astroglial-derived tumors and absent in oligodendrogliomas: concrete premises for a new reliable diagnostic marker in gliomas. Am. J. Surg. Pathol. 31 (2007) 760-769
18. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(- Delta Delta C(T)) Method. Methods 25 (2001) 402-408
19. Regina A., Jodoin J., Khoueir P., Rolland Y., Berthelet F., Moumdjian R., Fenart L., Cecchelli R., Demeule M., and Beliveau R. Down-regulation of caveolin-1 in glioma vasculature: modulation by radiotherapy. J. Neurosci. Res. 75 (2004) 291-299
20. Cordes N., Frick S., Brunner T.B., Pilarsky C., Grutzmann R., Sipos B., Kloppel G., McKenna W.G., and Bernhard E.J. Human pancreatic tumor cells are sensitized to ionizing radiation by knockdown of caveolin-1. Oncogene 26 (2007) 6851-6862
21. Muracciole X., Romain S., Dufour H., Palmari J., Chinot O., Ouafik L., Grisoli F., Branger D.F., and Martin P.M. PAI-1 and EGFR expression in adult glioma tumors: toward a molecular prognostic classification. Int. J. Radiat. Oncol. Biol. Phys. 52 (2002) 592-598
22. Czekay R.P., and Loskutoff D.J. Unexpected role of plasminogen activator inhibitor 1 in cell adhesion and detachment. Exp. Biol. Med. (Maywood) 229 (2004) 1090-1096
23. Czekay R.P., Aertgeerts K., Curriden S.A., and Loskutoff D.J. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J. Cell Biol. 160 (2003) 781-791
24. Wary K.K., Mariotti A., Zurzolo C., and Giancotti F.G. A requirement for caveolin-1 and associated kinase Fyn in integrin signaling and anchorage-dependent cell growth. Cell 94 (1998) 625-634
25. Wary K.K., Mainiero F., Isakoff S.J., Marcantonio E.E., and Giancotti F.G. The adaptor protein Shc couples a class of integrins to the control of cell cycle progression. Cell 87 (1996) 733-743
26. Wei Y., Yang X., Liu Q., Wilkins J.A., and Chapman H.A. A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling. J. Cell Biol. 144 (1999) 1285-1294
27. Boyd N.D., Chan B.M., and Petersen N.O. Beta1 integrins are distributed in adhesion structures with fibronectin and caveolin and in coated pits. Biochem. Cell Biol. 81 (2003) 335-348
28. Upla P., Marjomaki V., Kankaanpaa P., Ivaska J., Hyypia T., Van Der Goot F.G., and Heino J. Clustering induces a lateral redistribution of alpha 2 beta 1 integrin from membrane rafts to caveolae and subsequent protein kinase C-dependent internalization. Mol. Biol. Cell 15 (2004) 625-636
29. del Pozo M.A., Balasubramanian N., Alderson N.B., Kiosses W.B., Grande-Garcia A., Anderson R.G., and Schwartz M.A. Phospho-caveolin-1 mediates integrin-regulated membrane domain internalization. Nat. Cell Biol. 7 (2005) 901-908
30. Parsons-Wingerter P., Kasman I.M., Norberg S., Magnussen A., Zanivan S., Rissone A., Baluk P., Favre C.J., Jeffry U., Murray R., and McDonald D.M. Uniform overexpression and rapid accessibility of alpha5beta1 integrin on blood vessels in tumors. Am. J. Pathol. 167 (2005) 193-211
31. Kita D., Takino T., Nakada M., Takahashi T., Yamashita J., and Sato H. Expression of dominant-negative form of Ets-1 suppresses fibronectin-stimulated cell adhesion and migration through down-regulation of integrin alpha5 expression in U251 glioma cell line. Cancer Res. 61 (2001) 7985-7991
32. Kim S., Bell K., Mousa S.A., and Varner J.A. Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am. J. Pathol. 156 (2000) 1345-1362
33. Sawada K., Mitra A.K., Radjabi A.R., Bhaskar V., Kistner E.O., Tretiakova M., Jagadeeswaran S., Montag A., Becker A., Kenny H.A., Peter M.E., Ramakrishnan V., Yamada S.D., and Lengyel E. Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res. 68 (2008) 2329-2339
34. Galbiati F., Volonte D., Brown A.M., Weinstein D.E., Ben-Ze'ev A., Pestell R.G., and Lisanti M.P. Caveolin-1 expression inhibits Wnt/beta-catenin/Lef-1 signaling by recruiting beta-catenin to caveolae membrane domains. J. Biol. Chem. 275 (2000) 23368-23377
35. Lu Z., Ghosh S., Wang Z., and Hunter T. Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell 4 (2003) 499-515
36. Sanna E., Miotti S., Mazzi M., De Santis G., Canevari S., and Tomassetti A. Binding of nuclear caveolin-1 to promoter elements of growth-associated genes in ovarian carcinoma cells. Exp. Cell Res. 313 (2007) 1307-1317
37. Engelman J.A., Chu C., Lin A., Jo H., Ikezu T., Okamoto T., Kohtz D.Z., and Lisanti M.P. Caveolin-mediated regulation of signaling along the p42/44 MAP kinase cascade in vivo. A role for the caveolin-scaffolding domain. FEBS Lett. 428 (1998) 205-211
38. Cohen A.W., Park D.S., Woodman S.E., Williams T.M., Chandra M., Shirani J., Pereira de Souza A., Kitsis R.N., Russell R.G., Weiss L.M., Tang B., Jelicks L.A., Factor S.M., Shtutin V., Tanowitz H.B., and Lisanti M.P. Caveolin-1 null mice develop cardiac hypertrophy with hyperactivation of p42/44 MAP kinase in cardiac fibroblasts. Am. J. Physiol. Cell Physiol. 284 (2003) C457-474
39. Seftor R.E., Seftor E.A., Sheng S., Pemberton P.A., Sager R., and Hendrix M.J. maspin suppresses the invasive phenotype of human breast carcinoma. Cancer Res. 58 (1998) 5681-5685
40. Marinelli L., Meyer A., Heckmann D., Lavecchia A., Novellino E., and Kessler H. Ligand binding analysis for human alpha5beta1 integrin: strategies for designing new alpha5beta1 integrin antagonists. J. Med. Chem. 48 (2005) 4204-4207
41. Cue D., Southern S.O., Southern P.J., Prabhakar J., Lorelli W., Smallheer J.M., Mousa S.A., and Cleary P.P. A nonpeptide integrin antagonist can inhibit epithelial cell ingestion of Streptococcus pyogenes by blocking formation of integrin alpha 5beta 1-fibronectin-M1 protein complexes. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 2858-2863
42. Maglott A., Bartik P., Cosgun S., Klotz P., Ronde P., Fuhrmann G., Takeda K., Martin S., and Dontenwill M. The small alpha5beta1 integrin antagonist, SJ749, reduces proliferation and clonogenicity of human astrocytoma cells. Cancer Res. 66 (2006) 6002-6007
43. Bartik P., Maglott A., Entlicher G., Vestweber D., Takeda K., Martin S., and Dontenwill M. Detection of a hypersialylated beta1 integrin endogenously expressed in the human astrocytoma cell line A172. Int. J. Oncol. 32 (2008) 1021-1031
44. Stoeltzing O., Liu W., Reinmuth N., Fan F., Parry G.C., Parikh A.A., McCarty M.F., Bucana C.D., Mazar A.P., and Ellis L.M. Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int. J. Cancer 104 (2003) 496-503
45. Livant D.L., Brabec R.K., Pienta K.J., Allen D.L., Kurachi K., Markwart S., and Upadhyaya A. Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma. Cancer Res. 60 (2000) 309-320